GLP-1 dose personalization: what the science says vs. TikTok

What did @jacquicarvajal actually say?

Honestly? It is difficult to evaluate this video on its scientific merits because the available transcript is incoherent. The words do not match the caption's subject matter at all. The caption promises a message about individualized GLP-1 treatment, stating "it's not about using more, but using what your body needs" and that "each body responds differently." Those are reasonable premises. But the transcript itself contains gibberish about military personnel and civil rights that has no connection to medicine, GLP-1 therapy, or anything in the hashtags.

Two possibilities: the transcript was generated from a non-English audio track and failed badly, or there was a transcription error at the source. Either way, we cannot quote the creator directly on any medical claim because the transcript is not usable. What we can evaluate is the caption's core message, which is at least in the right neighborhood for GLP-1 education.

Does the science back the caption's premise up?

The caption's central idea, that GLP-1 dosing should be individualized rather than maximized, is actually well-supported. It is not a controversial take. The clinical evidence consistently shows that tolerability, not ceiling dose, should drive titration decisions for most patients.

The SCALE and SUSTAIN trial series for liraglutide and semaglutide respectively showed meaningful individual variation in weight loss and glycemic response at identical doses. Davies et al. (2021, The Lancet Diabetes and Endocrinology) noted that GI side effects, the main driver of dropout, were highly variable between patients at the same dose level. The SURMOUNT-1 trial for tirzepatide (Jastreboff et al., 2022, NEJM) confirmed that patients who stayed at lower maintenance doses due to tolerability still achieved clinically significant weight loss, just somewhat less on average than those who reached maximum dose. The key word there is "average." Individual responses diverged substantially.

So the caption is not wrong. Personalizing GLP-1 dosing is standard clinical practice, not a fringe opinion.

What did they get wrong, or right?

The caption gets credit for framing that resists the "more is better" mindset that has become common in weight-loss social media culture. That framing matters. Patients who push for maximum doses without clinical justification face higher rates of nausea, vomiting, and treatment discontinuation, which produces exactly the "temporary result" the caption warns against.

However, there are two problems worth naming. First, the video relies entirely on caption-level messaging. Without a coherent transcript we cannot confirm what clinical detail, if any, was actually delivered. A well-meaning caption attached to unintelligible or off-topic audio is not medical education. Second, phrases like "a sustainable change" and "correct adjustment" are vague enough to mean almost anything. Viewers already using GLP-1 medications could take this as encouragement to self-adjust doses, which is not appropriate. Dose changes on GLP-1 therapies should happen with a prescribing clinician, full stop. The caption does not say that, and that omission is a real gap.

What should you actually know?

If you are on a GLP-1 medication or considering one, here is what the evidence actually supports. Dose escalation protocols exist for a reason: they reduce GI side effects during the body's adjustment period. Skipping ahead or pushing past your tolerable dose does not reliably produce better long-term outcomes. Rubino et al. (2021, NEJM) found that stopping semaglutide led to weight regain regardless of what dose the patient had reached, which suggests that sustainability depends more on continued treatment than on peak dose achieved.

Individual response variation is real and documented. Genetics, gut microbiome composition, baseline insulin resistance, and medication adherence all influence outcomes. A patient losing 8 percent of body weight at a lower dose is not failing. They may simply be responding differently, which is normal.

• Never adjust your GLP-1 dose without talking to your prescriber first.
• GI side effects that persist beyond the titration window are a clinical signal, not something to push through alone.
• Compounded GLP-1 formulations are not equivalent to FDA-approved brand-name drugs. Do not assume they are.
• "Sustainable change" requires ongoing clinical follow-up, not just the right dose.